Mirae Asset Global Investments’s Spyre Therapeutics SYRE Stock Holding History

Mirae Asset Global Investments’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$345K	Sell	3,884 -213	-5%	-$15.5K	﹤0.01%	1037
2026 Q1	$207K	Buy	4,097 +327	+9%	+$12.3K	﹤0.01%	1066
2025 Q4	$124K	Buy	3,770 +1,435	+61%	+$37.5K	﹤0.01%	1223
2025 Q3	$39.1K	Buy	2,335 +4	+0.2%	+$65	﹤0.01%	1383
2025 Q2	$34.9K	Buy	2,331 +315	+16%	+$4.66K	﹤0.01%	1305
2025 Q1	$36.2K	Buy	2,016 +61	+3%	+$1.27K	﹤0.01%	1300
2024 Q4	$46.3K	Buy	+1,955	New	+$57.3K	﹤0.01%	1274

Other funds holding SYRE

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments's SYRE Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Spyre Therapeutics (SYRE) stake by 5.2% in Q2 2026, selling an estimated $15.5K and leaving 3,884 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Mirae Asset Global Investments first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 52 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Mirae Asset Global Investments held 3,884 shares of Spyre Therapeutics worth $345K as of Q2 2026.
Mirae Asset Global Investments sold 213 Spyre Therapeutics shares in Q2 2026, an estimated $15.5K.
Spyre Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1037 holding.
Mirae Asset Global Investments first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
52 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.